CompareMarketResearchRequest a sample
Home / Healthcare / RNA Therapeutics

Healthcare · Market report

RNA Therapeutics Market Size, Share and Forecast 2026-2036

The global RNA therapeutics market is worth USD 13.4 bn in 2026 and is forecast to reach USD 70.2 bn by 2036, growing at a 18.0% CAGR. United States is the largest country market and siRNA is the largest by modality segment.

USD 13.4 bnMarket size 2026
USD 70.2 bnForecast 2036
18.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global RNA therapeutics market is worth USD 13.4 bn in 2026 and is forecast to reach USD 70.2 bn by 2036, growing at a 18.0% CAGR. United States is the largest country market and siRNA is the largest by modality segment.

ScopeMedicines that act on RNA or use RNA as the drug, including small interfering RNA, antisense oligonucleotides and mRNA-based therapeutics (excluding infectious disease vaccines).
IndustryHealthcare
Value 2025USD 11.0 bn
Value 2026USD 13.4 bn
Value 2036USD 70.2 bn
CAGR 2026-203618.0%
Volume 2026136 thousand patients
Volume 2036829 thousand patients
Average price 2026USD 98,500 per patient
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

RNA Therapeutics market size and forecast, 2026-2036

Exhibit 1The global RNA therapeutics market is forecast to grow from USD 13.4 bn in 2026 to USD 70.2 bn by 2036, more than five times its 2026 sizeGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 18.0%
RNA Therapeutics market value, 2025 to 2036Market value by year. 2025: USD 11.0 bn; 2026: USD 13.4 bn; 2027: USD 15.8 bn; 2028: USD 18.7 bn; 2029: USD 22.0 bn; 2030: USD 26.0 bn; 2031: USD 30.7 bn; 2032: USD 36.2 bn; 2033: USD 42.7 bn; 2034: USD 50.4 bn; 2035: USD 59.5 bn; 2036: USD 70.2 bn. Compound annual growth rate 2026 to 2036: 18.0%.202513.4 bn202630.7 bn203170.2 bn203618.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 13.4 bn
2027USD 15.8 bn
2028USD 18.7 bn
2029USD 22.0 bn
2030USD 26.0 bn
2031USD 30.7 bn
2032USD 36.2 bn
2033USD 42.7 bn
2034USD 50.4 bn
2035USD 59.5 bn
2036USD 70.2 bn

RNA Therapeutics market segmentation

By modality

Exhibit 2siRNA is the largest segment by modality, with 48.0% of 2026 revenueEstimated share of 2026 global revenue, by modality
RNA Therapeutics market share by modality, 2026Share of 2026 revenue by modality. siRNA: 48.0%; Antisense oligonucleotides: 36.0%; Aptamers and others: 10.0%; mRNA therapeutics: 6.0%.siRNA48.0%Antisense oligonucleotides36.0%Aptamers and others10.0%mRNA therapeutics6.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
siRNA48.0%57.9%USD 6.4 bn20.2%
Antisense oligonucleotides36.0%19.9%USD 4.8 bn11.2%
mRNA therapeutics6.0%16.1%USD 805 mn30.3%
Aptamers and others10.0%6.1%USD 1.3 bn12.2%

By therapy area

Exhibit 3Cardiovascular and metabolic adds the most revenue by therapy area, growing from USD 3.2 bn in 2026 to USD 35.6 bn by 2036Estimated revenue in USD by therapy area, 2026 and 2036 forecast
RNA Therapeutics market by therapy area, 2026 and 2036Revenue by therapy area in 2026 and 2036. Cardiovascular and metabolic: USD 3.2 bn in 2026, USD 35.6 bn in 2036, change +1,004%; Rare and genetic disease: USD 5.1 bn in 2026, USD 17.7 bn in 2036, change +247%; Neurology: USD 3.8 bn in 2026, USD 11.9 bn in 2036, change +217%; Other: USD 1.3 bn in 2026, USD 5.1 bn in 2036, change +278%.20262036 forecastChangeCardiovascular and metabolic+1,004%3.2 bn35.6 bnRare and genetic disease+247%5.1 bn17.7 bnNeurology+217%3.8 bn11.9 bnOther+278%1.3 bn5.1 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Rare and genetic disease38.0%25.2%USD 5.1 bn13.2%
Cardiovascular and metabolic24.0%50.6%USD 3.2 bn27.1%
Neurology28.0%17.0%USD 3.8 bn12.2%
Other10.0%7.2%USD 1.3 bn14.2%

By delivery

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
GalNAc conjugates30.0%38.0%USD 4.0 bn20.8%
Lipid nanoparticles34.0%34.0%USD 4.6 bn18.0%
Naked oligonucleotides20.0%14.0%USD 2.7 bn13.9%
Viral and other vectors16.0%14.0%USD 2.1 bn16.4%

By route

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Subcutaneous50.0%54.0%USD 6.7 bn18.9%
Intravenous36.0%32.0%USD 4.8 bn16.6%
Intrathecal and local14.0%14.0%USD 1.9 bn18.0%

By development stage

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Commercial products62.0%52.0%USD 8.3 bn15.9%
Late clinical24.0%30.0%USD 3.2 bn20.7%
Platform and licensing revenue14.0%18.0%USD 1.9 bn21.0%

Top 25 countries for RNA therapeutics by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 94.0% of 2026 revenue and the 25 countries below together hold 98.2%.

Exhibit 4United States is the largest country market at USD 7.5 bn in 2026, and the three largest countries hold 71.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
RNA Therapeutics market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 7.5 bn, 56.0%; Germany: USD 1.1 bn, 8.0%; Japan: USD 939 mn, 7.0%; China: USD 671 mn, 5.0%; France: USD 537 mn, 4.0%; United Kingdom: USD 537 mn, 4.0%; Italy: USD 403 mn, 3.0%; Spain: USD 403 mn, 3.0%; Canada: USD 268 mn, 2.0%; Brazil: USD 268 mn, 2.0%.United States7.5 bn 56.0%Germany1.1 bn 8.0%Japan939 mn 7.0%China671 mn 5.0%France537 mn 4.0%United Kingdom537 mn 4.0%Italy403 mn 3.0%Spain403 mn 3.0%Canada268 mn 2.0%Brazil268 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 7.5 bn56.0%USD 36.7 bn17.2%
2GermanyUSD 1.1 bn8.0%USD 5.7 bn18.1%
3JapanUSD 939 mn7.0%USD 4.6 bn17.1%
4ChinaUSD 671 mn5.0%USD 6.3 bn25.1%
5FranceUSD 537 mn4.0%USD 2.9 bn18.3%
6United KingdomUSD 537 mn4.0%USD 2.9 bn18.3%
7ItalyUSD 403 mn3.0%USD 2.0 bn17.2%
8SpainUSD 403 mn3.0%USD 2.0 bn17.2%
9CanadaUSD 268 mn2.0%USD 1.3 bn17.4%
10BrazilUSD 268 mn2.0%USD 1.7 bn20.2%
11SwitzerlandUSD 125 mn0.9%USD 625 mn17.5%
12NetherlandsUSD 75 mn0.6%USD 372 mn17.4%
13AustraliaUSD 55 mn0.4%USD 274 mn17.4%
14South KoreaUSD 44 mn0.3%USD 225 mn17.6%
15BelgiumUSD 38 mn0.3%USD 190 mn17.6%
16SwedenUSD 32 mn0.2%USD 162 mn17.5%
17DenmarkUSD 30 mn0.2%USD 148 mn17.4%
18IsraelUSD 27 mn0.2%USD 190 mn21.6%
19MexicoUSD 24 mn0.2%USD 169 mn21.4%
20IndiaUSD 23 mn0.2%USD 162 mn21.6%
21TurkeyUSD 20 mn0.1%USD 148 mn22.0%
22AustriaUSD 19 mn0.1%USD 98 mn18.0%
23TaiwanUSD 19 mn0.1%USD 91 mn17.1%
24PolandUSD 17 mn0.1%USD 126 mn21.9%
25Saudi ArabiaUSD 16 mn0.1%USD 119 mn22.2%
Rest of worldUSD 242 mn1.8%USD 1.2 bn17.3%
Exhibit 5United States and China account for 61% of the USD 56.8 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
RNA Therapeutics market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 13.4 bn. United States: +USD 29.1 bn; China: +USD 5.7 bn; Germany: +USD 4.6 bn; Japan: +USD 3.6 bn; France: +USD 2.3 bn; 20 other countries: +USD 10.5 bn; Rest of world: +USD 945 mn. Market value 2036: USD 70.2 bn.Market value 202613.4 bnUnited States+29.1 bnChina+5.7 bnGermany+4.6 bnJapan+3.6 bnFrance+2.3 bn20 other countries+10.5 bnRest of world+945 mnMarket value 203670.2 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Novartis
  • Biogen
  • Novo Nordisk
  • Moderna
  • BioNTech
  • Pfizer

Group 2: Regional and specialist players

  • Arrowhead Pharmaceuticals
  • Sarepta Therapeutics
  • Wave Life Sciences
  • Arcturus Therapeutics
  • Dyne Therapeutics
  • Stoke Therapeutics

Group 3: Emerging and niche players

  • Silence Therapeutics
  • Arbutus Biopharma
  • Sirnaomics
  • ProQR Therapeutics
  • Korro Bio
  • Suzhou Ribo Life Science

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the RNA therapeutics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 18.0% is calculated from the resulting values.

The market is divided by modality, by therapy area, by delivery, by route, by development stage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the RNA therapeutics market?

The global RNA therapeutics market is estimated at USD 11.0 bn in 2025 and USD 13.4 bn in 2026.

How fast will the RNA therapeutics market grow?

It is forecast to reach USD 70.2 bn by 2036, a compound annual growth rate of 18.0% from 2026, an increase of USD 56.8 bn.

Which country is the largest market for RNA therapeutics?

United States is the largest market by revenue at USD 7.5 bn in 2026, 56.0% of the global total. The three largest countries together hold 71.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 25.1% a year from 2026 to 2036.

Which RNA therapeutics segment is largest?

In the by modality split, siRNA is the largest segment with 48.0% of 2026 revenue.

Who are the leading RNA therapeutics companies?

Global leaders include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Biogen.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Proton Therapy Radiopharmaceuticals →

All Healthcare markets →

Request a sample